Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

[1] Bai RY(2000)Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway Blood 96 4319-4327

[2] Ouyang T(1997)Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis Mol Cell Biol 17 2312-2325

[3] Miething C(2002)Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin Cancer Res 62 1559-1566

[4] Morris SW(2010)Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors Biochemistry 49 6813-6825

[5] Peschel C(2012)Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 1011-1019

[6] Duyster J(2013)Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors Mol Cancer Res 11 122-132

[7] Bischof D(2008)Oncogenic mutations of ALK kinase in neuroblastoma Nature 455 971-974

[8] Pulford K(2010)Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Cancer Res 70 9827-9836

[9] Mason DY(2003)NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood 101 1919-1927

[10] Morris SW(2005)Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target Nat Med 11 623-629

[1] Bai RY(2000)Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway Blood 96 4319-4327

[2] Ouyang T(1997)Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis Mol Cell Biol 17 2312-2325

[3] Miething C(2002)Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin Cancer Res 62 1559-1566

[4] Morris SW(2010)Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors Biochemistry 49 6813-6825

[5] Peschel C(2012)Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 1011-1019

[6] Duyster J(2013)Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors Mol Cancer Res 11 122-132

[7] Bischof D(2008)Oncogenic mutations of ALK kinase in neuroblastoma Nature 455 971-974

[8] Pulford K(2010)Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Cancer Res 70 9827-9836

[9] Mason DY(2003)NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood 101 1919-1927

[10] Morris SW(2005)Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target Nat Med 11 623-629